Clascoterone vs Minox***: Which Mechanism Is Different and Why?
By ClascoteroneX Editorial Team — we summarise published research on clascoterone and cite primary sources. Educational content, not medical advice.
Minox*** has been the default topical for androgenetic alopecia for four decades. Clascoterone is the newer entrant, and the most common question is which one is better. The more useful question is what each one actually does, because they intervene at completely different points in the hair cycle.
The core mechanistic difference
Minox*** is a potassium channel opener. Its active metabolite promotes vasodilation and prolongs the anagen phase, pushing telogen follicles back into growth. It does nothing to the androgen signal that caused the miniaturisation in the first place.
Clascoterone is an androgen receptor antagonist. It competes with DHT for the receptor inside the dermal papilla, targeting the upstream driver of patterned hair loss rather than the downstream growth phase.
In short: Minox*** pushes the follicle to grow; clascoterone blocks the signal that shrinks it.
Side by side
| Clascoterone | Minox*** | |
|---|---|---|
| Target | Androgen receptor (dermal papilla) | Potassium channels / vasculature |
| Addresses cause | Yes — androgen signalling | No — growth-phase extension |
| Route | Topical solution | Topical solution or foam |
| Systemic exposure | Rapidly metabolised to inactive cortexolone | Measurable systemic absorption |
| Typical early sign | Reduced shedding | Initial shedding, then regrowth |
| Evidence maturity | Phase III in acne; Phase II/III in alopecia | Decades of approved use |
The shedding question
Minox*** commonly produces a temporary increase in shedding in the first four to eight weeks as synchronised telogen hairs are released before new anagen hairs replace them. It is expected and self-limiting, but it is a well-known reason people stop early.
Clascoterone does not force that cycle reset. Its early observable endpoint tends to be the opposite direction — a gradual reduction in daily shed count as receptor-driven miniaturisation pressure eases.
Tolerability and formulation
Minox*** solutions often contain propylene glycol, a frequent cause of scalp irritation and contact dermatitis, which is why foam formulations exist. Reported adverse effects also include unwanted facial hair growth and, less commonly, cardiovascular symptoms related to systemic absorption.
In its large Phase III acne programme, topical clascoterone's local reactions were predominantly mild and application-site limited, and laboratory monitoring did not show clinically meaningful hormonal disturbance in adults.
Can they be used together?
Mechanistically they are complementary rather than redundant: one addresses androgen signalling, the other prolongs anagen. Many clinicians consider combination approaches for this reason.
That said, combining actives increases the chance of scalp irritation and makes it harder to attribute a result — or a side effect — to a single product. If you intend to layer them, do it with clinical supervision and introduce one at a time.
References
- Hebert A, et al. Topical Clascoterone Cream 1%: Two Phase 3 Randomized Clinical Trials. — JAMA Dermatology, 2020
- Mechanisms of action in topical hair-growth research. — British Journal of Dermatology
- Rosette C, et al. Cortexolone 17α-propionate as a novel androgen receptor antagonist. — Journal of Drugs in Dermatology
- SCALP 1 Phase III trial of clascoterone solution (NCT05910450). — ClinicalTrials.gov
- SCALP 2 Phase III trial of clascoterone solution (NCT05914805). — ClinicalTrials.gov
- Phase III results announcement for topical clascoterone solution. — Clinical trial update
This library is educational. For the product itself — formulation, routine, pricing and shipping terms — return to the main website.
View the product